Research programme: RNA targeted therapeutics - RaNA Therapeutics

Drug Profile

Research programme: RNA targeted therapeutics - RaNA Therapeutics

Latest Information Update: 09 May 2016

Price : $50

At a glance

  • Originator RaNA Therapeutics
  • Class Oligonucleotides
  • Mechanism of Action RNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Friedreich's ataxia; Spinal muscular atrophy
  • Research Inflammation; Musculoskeletal disorders

Most Recent Events

  • 09 May 2016 RaNA Therapeutics in-licenses RNA technology patent from Massachusetts General Hospital
  • 09 May 2016 RaNA Therapeutics has more that 150 patents pending for transcriptional and post-transcriptional activation platform in USA
  • 09 May 2016 RaNA Therapeutics receives patent allowance for RaNA’s transcriptional activation platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top